Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutetinib in EGFR rare-mutation NSCLC
CTR20190681Phase 2Completed
- Sponsor
- Suzhong Pharmaceutical Group Co., Ltd.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sutetinib in non-small cell lung cancer (NSCLC), sponsored by Suzhong Pharmaceutical Group Co., Ltd.. Started Apr 2019; status: completed.
02
Drugs
sutetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190681.